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Cardiac AT2R expression is upregulated in the normal process of aging. In this study we determined the contribution of AT2Rt o
chronic antihypertensive and remodelling eﬀects of AT1R blockade in aged hypertensive rats. Adult (20 weeks) and senescent (20
months)spontaneouslyhypertensiverats(SHRs)weretreatedwitheithertheAT1Rantagonist,candesartancilexetil(2mg/kg/day),
the AT2R antagonist, PD123319 (10mg/kg/day), or a combination of the 2 compounds. Mean arterial pressure (MAP) and left
ventricular volume were markedly decreased by candesartan cilexetil, however, simultaneous treatment with PD123319 had no
additional eﬀect on either parameter. Perivascular ﬁbrosis was signiﬁcantly reduced by candesartan cilexetil in aged animals only,
and this eﬀect was reversed by concomitant PD123319 administration. Vascular hypertrophy was reduced by candesartan cilexetil,
and these eﬀects were reversed by simultaneous PD123319. These results suggest that AT2R stimulation does not signiﬁcantly
inﬂuence the antihypertensive eﬀect of chronic AT1R blockade, but plays a role in the regulation of vascular structure. The
severe degree of cardiac perivascular ﬁbrosis in senescent animals was regressed by AT1R blockade and this eﬀect was reversed
by simultaneous AT2R inhibition, demonstrating an antiﬁbrotic role of AT2R stimulation in the aging hypertensive heart.
1.Introduction
The incidence of hypertension, cardiac hypertrophy, and
heart failure increases signiﬁcantly with aging [1], and age-
related structural adaptations may contribute to deteriorat-
ing function of the cardiovascular system. The aging heart
is characterised by myocyte loss, hypertrophy of remaining
cells, and exaggerated accumulation of extracellular (ECM)
proteins [1, 2], which is associated with increased incidence
of both contractile and conductile dysfunction of senescent
hearts [2]. In addition, structural modiﬁcations of the
aortaandcoronaryvasculature,particularlyinvolvinghyper-
trophy/hyperplasia of smooth muscle cells and increased
collagen deposition within and surrounding the media of
vessels [3], result in arterial stiﬀening, alterations in vascular
permeability, and deterioration of coronary haemodynamics
[4].
Ang II is known to promote cardiovascular hypertrophy
and ﬁbrosis via AT1R stimulation [5, 6], whereas the role
of AT2R has been less conclusively deﬁned [7]. AT2R
activationis thoughttooppose AT1R-mediated hypertrophic
and ﬁbrotic eﬀects; however, studies in transgenic mouse
models of targeted deletion [8, 9] or overexpression [10]
of AT2R have reported contrasting eﬀects on cardiovascular
structure, emphasising the need for further pharmacological
investigation and elucidation of AT2R function.
AT1R antagonists increase circulating levels of Ang
II, which may stimulate unopposed AT2R and potentially
contribute to the eﬀects of AT1Rb l o c k a d e[ 11]. We have
previously shown that impaired in vitro AT2R-mediated
relaxation in SHRs was restored by antihypertensive treat-
ment [12]. Furthermore, AT2R stimulation may inﬂuence
cardiovascular function and structure during chronic AT1R2 International Journal of Hypertension
blockade [13–15]. These studies have been performed in
animal models of genetic hypertension or following car-
diovascular infarct and have deduced various degrees of
AT2R-mediated antihypertrophic and antiﬁbrotic eﬀects,
depending on the study.
Importantly, although cardiac AT2R expression is rela-
tively low in the adult rat heart [16], expression may be
upregulatedincertaindiseasestatesandhasbeenparticularly
associated with conditions of increased ﬁbrosis [17], cardiac
hypertrophy [18], heart failure [19], and also with increasing
age [20, 21]. Moreover, increased myocardial angiotensino-
gen and ACE indicate that intracardiac production of Ang II
may also be potentiated with senescence [22].
Given the possibility of augmented cardiac RAS activity
with increased age, and also the fact that chronic AT1R
blockade increased longevity in rodent models of aging
and was associated with cardiovascular protective eﬀects
[23, 24], we reasoned that a greater AT2R contribution to
AT1R inhibition may be manifest in the aged hypertensive
state. Therefore, the aims of this study were to determine
the contribution of the AT2R to the antihypertensive and
cardiovascular remodelling eﬀects of chronic AT1R blockade
in aged SHRs.
2.MaterialsandMethods
2.1. Animals and Treatment. Male SHRs (12 weeks) were
obtained from the Animal Resource Centre, Western Aus-
traliaandweremaintainedona12-hourday/nightcyclewith
free access to food and water until animals were either 20
weeks or 20 months of age. Senescent animals were used
at 20 months, as at this age, SHRs display many of the
features of hypertensive and age-related cardiac remodelling
(including cardiovascular hypertrophy and ﬁbrosis) but are
yet to complete the transition to heart failure [25].
Radiotelemetry transmitters (TA11PA-C40, Data Sci-
ences) were inserted into the abdominal aorta of SHRs
under isoﬂurane anaesthesia (2–4%, O2), as previously
described [26]. Animals were allowed to recover for 1
week, after which time a continuous baseline recording
of MAP and HR was made for a further week. Animals
were then given the AT1R antagonist, candesartan cilexetil
(2mg/kg/day), its vehicle, or the nonangiotensin antihyper-
tensive, hydralazine (30mg/day), in drinking water. At the
same time, senescent SHRs were also brieﬂy anaesthetised
with isoﬂurane, and osmotic mini pumps containing either
PD123319 (10mg/kg/day) or saline vehicle were inserted
into a subcutaneous pocket formed between the scapulae.
Doses of candesartan cilexetil and PD123319 were based on
previous studies performed in senescent Wistar Kyoto rats
[26] .A d u l tS H R sw e r et r e a t e df o r2w e e k sw i t hc a n d e s a r t a n
cilexetil (2mg/kg/day), before implantation of osmotic mini
pumps, such that animals received the combination of 6-
week candesartan cilexetil and 4-week PD123319 treatment.
In senescent SHRs, all drug treatments were initiated simul-
taneously and continued for 4 weeks duration. MAP and HR
were recorded continuously during the entire 4- or 6-week
treatment period. Treatment groups were as follows:
Adult (20 weeks) SHRs
(i) control (n = 6),
(ii) candesartan cilexetil alone (n = 7),
(iii) candesartan cilexetil + PD123319 (n = 7),
(iv) PD123319 alone (n = 7).
Senescent (20 months) SHRs
(i) control (n = 10),
(ii) candesartan cilexetil alone (n = 9),
(iii) candesartan cilexetil + PD123319 (n = 9),
(iv) PD123319 alone (n = 4),
(v) hydralazine (n = 7).
2.2. Determination of Plasma Ang II Levels. At the end of the
treatment period, a sample of blood was collected directly
from the catheterised aorta of each animal into chilled,
heparinised tubes, and then centrifuged at 4000rpm at 4◦C
for10minutestoisolateplasma.Theresultantplasmasample
was stored at −80◦C for later analysis. Ang II concentrations
were analysed in duplicate by RIA as described previously
[27]. Brieﬂy, plasma (100µL) was equilibrated with antibody
raised in rabbit against Ang II, which was N-terminally
conjugated to bovine thyroglobulin. Monoiodinated 125I-
Ang II tracer (10 000 cpm in 100µL) was added and allowed
to equilibrate for 16hrs at 4◦C, whereupon bound and
free phase was separated using Dextran 10-coated charcoal
and centrifugation. Sensitivity was 3.5pg/mL. Intra- and
interassayvariabilitieswere6.4and12.0%.Crossreactivityto
other angiotensins were Ang I = 0.52%, Ang (1–7) = 0.01%,
and to all other pertinent hormones less than 0.10%.
2.3.PerfusionFixation. After4or6weekstreatment,animals
were anaesthetised (ketamine/xylazine; 100mg/10mg per
kg), and the abdominal aorta brieﬂy ligated to enable
removal of the radiotelemetry probe. A catheter was inserted
into the abdominal aorta, and a sample of blood was
collected into a heparinised tube. Heparin sodium (1IU/g
body weight), papaverine hydrochloride (1.2mg/rat), and
potassium chloride (60mM in 0.1mL) were administered
via the catheterized aorta to prevent blood from clotting,
maximally dilate blood vessels, and arrest the heart in
diastole, respectively. Organs were cleared of blood with
physiological saline, and then perfusion ﬁxed with 4%
paraformaldehyde in 0.1M phosphate buﬀer. Perfusion
pressure was maintained at a pressure corresponding to the
in vivo systolic pressure of adult and aged SHRs by use of
a perfusion apparatus attached to a sphygmomanometer.
Hearts and blood vessels were then excised and stored
immersed in paraformaldehyde at 4◦C for later processing.
2.4. Cardiac Remodelling. Both left and right atria were
removed from ﬁxed hearts, and the remaining left ventricle
(LV), right ventricle (RV), and septum were weighed. Hearts
were then cut into approximately twelve 1.5mm thick slices
using a razor blade slicing device. Each slice was thenInternational Journal of Hypertension 3
Table 1: Eﬀect of drug treatments on body weight, ventricular weight, and plasma Ang II of adult and senescent SHRs.
Control Candesartan cilexetil Candesartan cilexetil +
PD123319 PD123319 Hydralazine
Body weight (g)
Adult SHRs 411 ± 11 415 ± 5 410 ± 5 414 ± 3—
Senescent SHRs 417 ± 9 427 ± 7 428 ± 10 399 ± 9 419 ± 11
Ventricular weight (mg)
Adult SHRs 1423 ± 23 1229 ± 39∗ 1207 ± 30∗ 1474 ± 48 —
Senescent SHRs 2114 ± 74 1796 ± 85∗ 1962 ± 86 2136 ± 163 1952 ± 49
Plasma Ang II (pg/mL)
Adult SHRs 220 ± 100 1597 ± 234∗ 2785 ± 817∗ 68 ± 18 —
Senescent SHRs 80 ± 10 383 ± 89∗ 271 ± 51∗ 64 ± 23 91 ± 16
Values are mean ± SEM. ∗P<0.05 versus age-matched control (1-way ANOVA).
placed on a light table, images were captured using a video
camera module (Sony, XC-77CE CCD, Japan) displayed
on a monitor, and analysed using imaging computer soft-
ware (Microscope Computed Imaging Device M4 (MCID),
Imaging Research, Canada). Sampled cross-sectional areas
of the LV, RV, and both LV and RV chambers were then
multiplied by slice thickness to calculate the volume of
each sampled area. Total volumes of LV, RV, LV chamber
and RV chamber of each heart were determined by adding
measurements taken from heart slices throughout the entire
heart. Ventricular weight and volume measurements were
normalized to body weight for each animal.
2.5. Interstitial and Perivascular Fibrosis in the Heart. After
heart volumes had been determined, ﬁve 1.5mm heart slices
from each animal were embedded in paraﬃn, sectioned at
5µm and stained for collagen with 0.001% Picrosirius Red.
Eachsectionwasviewedunderalightmicroscope(Olympus,
BH-2, Japan) with a video camera module interfaced to
a computer. Images were displayed onto a monitor and
analysed using imaging computer software (MCID). All
sections were examined under ×200 magniﬁcation.
The area of interstitial ﬁbrosis in 6 ﬁelds of view of the
L Vp e rs e c t i o na n d2ﬁ e l d so fv i e wo ft h eR Vp e rs e c t i o n
were sampled, and the percentage of ﬁbrosis within each
sampled area was averaged for each animal. Collagen volume
fraction (%) was calculated by determining the area stained
forcollagenasapercentageofthetotalareaofsampledtissue,
per ﬁeld of view. Perivascular ﬁbrosis was investigated in
the LV only. Two intramyocardial arterioles (measuring 100–
200µm in diameter) were randomly selected per section.
The cross-sectional area (CSA) of adventitia (representing
perivascular ﬁbrosis), media, and lumen were determined
and averaged for each animal. Perivascular ﬁbrosis was
normalised to lumen area. As an index of microvascular
remodelling, media-to-lumen ratio of intramyocardial ves-
sels was determined from CSA measurements and averaged
for each animal.
2.6. Aortic Hypertrophy. Segments of ﬁxed vessel were
dissected from the thoracic portion of the aorta of each
animal, embedded in epon-araldite, cut at 1µm, and stained
with toluidine blue. Each section was viewed under a
light microscope and analysed using imaging computer
software (MCID). All sections were examined under ×100
magniﬁcation. CSA of the media was determined for each
vessel and normalised to lumen CSA.
2.7. Statistics. The eﬀect of drug treatments on MAP and
HR over time was assessed by one- or two-way analysis of
variance (ANOVA) with repeated measures, as appropriate.
Diﬀerences in morphometric data between treatments were
determined using one-way ANOVA, followed by a Bonfer-
roni post hoc test. Results are expressed as mean ± standard
errorofthemean(SEM).Statisticalsigniﬁcancewasaccepted
as a probability of P<0.05.
3. Results
3.1. Body Weight and Plasma Ang II. Body weight was not
aﬀected by any drug treatments (Table 1). Compared to
age-matched untreated animals, plasma Ang II levels were
increased more than 7- and 3-fold by candesartan cilexetil
treatment, either alone or in combination with PD123319,
in adult and senescent SHRs, respectively (Table 1). Both
PD1231319 alone and hydralazine had no eﬀect on plasma
Ang II levels (Table 1).
3.2. Blood Pressure and Heart Rate in Senescent SHRs. Can-
desartan cilexetil caused a marked reduction in MAP com-
pared to control animals, and administration of PD123319
did not reverse this antihypertensive eﬀect, in either adult or
senescent animals (Figures 1(a) and 1(c)). MAP was unaf-
fected by PD123319 alone. In senescent SHRs, hydralazine
caused a reduction in MAP that was similar in magnitude
to that caused by AT1Rb l o c k a d e( Figure 1(c)). Candesartan
cilexetil and hydralazine increased HR at the initiation of
antihypertensive treatment in both age groups, which most
likely represents a reﬂex tachycardia which persisted for 2-3
days until resetting of the baroreﬂex occurred. HR after this
initial period was unaﬀected by treatments (Figures 1(b) and
1(d)).4 International Journal of Hypertension
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Figure 1: Radiotelemetry recordings of (a) MAP and (b) HR of adult SHRs, at baseline and during treatment with vehicle (control, n = 6),
candesartan cilexetil (2mg/kg/day) alone (n = 7) or in combination with PD123319 (10mg/kg/day, n = 7), or PD123319 alone. Analogous
radiotelemetry recordings of (c) MAP and (d) HR of senescent SHRs, at baseline and during treatment with vehicle (control, n = 10),
candesartan cilexetil alone (n = 9) or in combination with PD123319 (n = 9), PD123319 alone (n = 4), or hydralazine (30mg/kg/day,
n = 7). ∗∗P<0.01 versus control (2-way ANOVA).
3.3. Cardiac Remodelling. Ventricular weight (Table 1), ven-
tricular weight to body weight ratio (Figure 2(a)) and LV
volume to body weight ratio (Figure 2(b)) of adult SHRs
were reduced by candesartan cilexetil; however, this antihy-
pertrophic action was not further inﬂuenced by simultane-
ous AT2R inhibition. Similarly, ventricular weight (Table 1),
ventricular weight to body weight ratio (Figure 2(c)), and
LV volume to body weight ratio (Figure 2(d)) of senescent
SHRs were also decreased by AT1R blockade. Furthermore,
the regression of both ventricular weight and ventricular
weight to body weight ratio were partially reversed by
concurrentPD123319treatment,suchthattheseindiceswere
not signiﬁcantly diﬀerent from control values. There were no
eﬀectsofdrugtreatmentsonRV,LVchamberorRVchamber,
volume to body weight ratios (data not shown).
3.4. Interstitial and Perivascular Fibrosis. Representative
light micrographs of perivascular and interstitial ﬁbrosis
of senescent SHRs are shown in Figure 3.G r o u pd a t a
shows that neither left (Figures 4(a) and 4(c)) nor right
(Figures 4(b) and 4(d)) ventricular interstitial ﬁbrosis
of adult and senescent SHRs were altered by any drug
treatments. Likewise, perivascular ﬁbrosis of adult SHRs was
not inﬂuenced by AT1 or AT2R inhibition (Figure 5(a)). In
contrast, perivascular ﬁbrosis was signiﬁcantly decreased by
∼28% in senescent SHRs receiving candesartan cilexetil, and
this eﬀect was completely reversed by simultaneous AT2R
blockade (Figure 5(b)).
3.5. Vascular Hypertrophy. Media to lumen ratios of aortic
vessels in both adult and senescent SHRs (Figures 6(a)
and 6(c)) and intramyocardial vessels of senescent SHRs
(Figure 6(d)) were decreased by candesartan cilexetil, and
this antihypertrophic eﬀect of AT1Rb l o c k a d ew a sr e v e r s e d
by concomitant PD123319 administration. Hydralazine also
caused a signiﬁcant reduction in media-to-lumen ratiosInternational Journal of Hypertension 5
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Figure 2: (a) Ventricular weight to body weight (BW) ratio and (b) left ventricular (LV) volume to body weight ratio of adult SHRs, at
baseline and during treatment with vehicle (control, n = 4), candesartan cilexetil (2mg/kg/day) alone (n = 4), or in combination with
PD123319 (10mg/kg/day, n = 4), and PD123319 alone (n = 7). (c) Ventricular weight to BW ratio and (d) LV volume to BW ratio of
senescent SHRs, at baseline and during treatment with vehicle (control, n = 10), candesartan cilexetil (2mg/kg/day) alone (n = 9), or in
combination with PD123319 (10mg/kg/day, n = 9), PD123319 alone (n = 4), or hydralazine (30mg/kg/day, n = 7). ∗P<0.05 versus
control (1-way ANOVA).
of aortic (Figure 6(b)) and intramyocardial (Figure 6(d))
vessels of senescent SHRs.
4. Discussion
We have shown for the ﬁrst time, a role for AT2Ri n
cardiac and vascular remodelling in a clinically relevant
animal model of aging and hypertension. Notably, AT2R
stimulation by endogenously raised Ang II levels contributed
to the cardiac antiﬁbrotic and vascular antihypertrophic
eﬀects of chronic AT1R blockade. Thus, this study highlights
the importance of AT2R in the chronic regulation of
cardiovascular structure in the aging hypertensive heart and
vasculature.
Candesartan cilexetil caused a marked reduction in
MAP in both adult and senescent SHRs, which was not
further aﬀected by AT2R blockade. These results imply that
stimulation of the AT2R does not signiﬁcantly inﬂuence
chronic blood pressure regulation and is consistent with
other long-term studies that showed either no [13, 14, 28]
or minimal [15] reversal of AT1R-blocker- (ARB-) mediated
blood pressure-lowering by simultaneous AT2R blockade
in SHRs. These ﬁndings are in direct contrast to the
acute setting, in which the antihypertensive eﬀect of ARB
compounds was reversed by simultaneous AT2R blockade
with PD123319 [29–31]. In addition, acute stimulation of
AT2R has also been shown to lower blood pressure in rats,
supportingaroleforAT2Rinacutebloodpressureregulation
[32–35].
Since both human and animal studies have shown
circulating Ang II and renin levels to be reduced with
increasing age [22, 36, 37], it is possible that the absence
of AT2R-mediated actions on blood pressure in aged SHRs
is due to depressed systemic RAS activity in senescence.
However, in this study we have shown a similar inability
of PD123319 to reverse the ARB-induced reduction in6 International Journal of Hypertension
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Figure 3: Representative light micrographs of cardiac (a–e) perivascular and (f–j) interstitial ﬁbrosis in senescent SHRs treated with (a, f)
vehicle (control), (b, g) candesartan cilexetil (2mg/kg/day), (c, h) candesartan cilexetil in combination with PD123319 (10mg/kg/day), (d,
i) PD123319 alone, or (e, j) hydralazine (30mg/kg/day). Scale bar = 50µm.
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Interstitial collagen volume fraction of (c) left and (d) right ventricles of senescent SHRs treated with vehicle (control, n = 10), candesartan
cilexetil alone (n = 9) or in combination with PD123319 (n = 9), PD123319 alone (n = 4), or hydralazine (30mg/kg/day, n = 7).International Journal of Hypertension 7
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Figure 5: (a) Perivascular ﬁbrosis of adult SHRs treated with vehicle (control, n = 6), candesartan cilexetil (2mg/kg/day) alone (n = 7)
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or hydralazine (30mg/kg/day, n = 7). Perivascular ﬁbrosis of intramyocardial arterioles, calculated as cross-sectional area of adventitia to
lumen ratio. ∗P<0.05 versus control (1-way ANOVA).
blood pressure in both adult and senescent rats. Moreover,
even though baseline levels of Ang II are relatively low in
aged SHRs compared to adult SHRs (∼3-fold lower than
adult SHRs, Table 1), AT1R inhibition caused an increase
in plasma Ang II of 3-4-fold, suggesting that the RAS is
still sensitive to perturbation in aged SHRs. Moreover, local
tissue production of Ang II has been shown to be elevated
in aged humans [6] and rodents [38]. Thus it is more likely
that the inability of PD123319 administration to reverse
ARB-induced antihypertensive eﬀects in the current context
reﬂects a subtle inﬂuence of AT2R stimulation on blood
pressure regulation being masked by the dominant impact
of AT1Rb l o c k a d e .
Candesartan cilexetil decreased indices of cardiac growth
of adult rats (ventricular weight, and LV volume to body
weight ratios), and PD123319 administration had no further
inﬂuence on these parameters, suggesting no major role for
AT2R in cardiac hypertrophy. Other studies in hypertensive
modelshavealsoreportedthatPD123319administrationdid
not signiﬁcantly reverse cardiac hypertrophy [15, 19, 28],
and additionally, AT2R were deduced to have no major
function in the regulation of cardiac mass from studies
in transgenic mice models of targeted deletion or cardiac-
speciﬁc over expression of AT2R[ 10, 39, 40]. In contrast, a
dependence on AT2R for ARB-mediated cardiac remodelling
following MI has been demonstrated in rats [13]a n d
AT2R knock out mice [40]. These mismatches in reported
AT2R inﬂuence on cardiac hypertrophy most likely reﬂect
the gross measures of cardiac hypertrophy made in the
majority of studies, as heart mass is commonly employed as
a surrogate marker for cardiac hypertrophy (i.e., increased
cardiomyocyte size) but is unable to distinguish between
changes in proportion of speciﬁc components within the
heart.
Indeed,ventricularweightandLVvolumetobodyweight
ratios were also reduced by AT1Rb l o c k a d ei ns e n e s c e n t
SHRs; however, in these aged animals, simultaneous AT2R
inhibition caused a partial reversal of ventricular weight
to body weight ratio. Given that LV volume is heavily
inﬂuenced by changes in cardiomyocyte area [2], and that
LVvolumewasnotinﬂuencedbyAT2Rblockade,PD123319-
mediated reversal of heart weight to body weight ratio most
likely reﬂects changes in the nonmyocyte components of
the heart, rather than a true eﬀect on cardiac hypertrophy.
Indeed, we have shown that perivascular ﬁbrosis of coronary
microvessels is decreased by AT1R blockade and that this
eﬀect is reversed by concomitant AT2R blockade, but only
in senescent hearts. We have previously shown a similar
mismatch between LV volume and ventricular weight fol-
lowing AT1R blockade in senescent normotensive WKY rats
[26], which also coincided with a cardiac AT2R-mediated
antiﬁbrotic action. Thus the PD122319-mediated increase
in ventricular weight to body weight ratio during AT1R
blockade may in fact be due to inhibition of an AT2R-
mediated antiﬁbrotic action in senescent SHRs.
Surprisingly,candesartancilexetildidnotreduceintersti-
tial ﬁbrosis in either adult or senescent SHRs. In the present
study, particularly high levels of LV and RV interstitial
ﬁbrosis (collagen volume fraction ∼7–10%) were seen in
control senescent animals. These relatively high levels of
interstitial ﬁbrosis in aged hearts are entirely consistent with
previous studies [15, 20], and contrast with the degree
of ﬁbrosis in adult hypertensive SHRs (interstitial collagen
volume fraction ∼4-5%). We have previously shown that
an identical treatment regime markedly reduced interstitial
ﬁbrosis from similar levels in aged normotensive WKY
(interstitial collagen volume fraction ∼4-5%), and this eﬀect
was also reversed by PD123319 [26]. Thus in the current8 International Journal of Hypertension
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Figure 6: Media to lumen ratio of (a) aortic and (b) intramyocardial vessels of adult SHRs treated with vehicle (control, n = 6), candesartan
cilexetil (2mg/kg/day) alone (n = 7) or in combination with PD123319 (10mg/kg/day, n = 7) or PD123319 alone (n = 7). Media to lumen
ratioof(c)aorticand(d)intramyocardialvesselsofsenescentSHRstreatedwithvehicle(control,n = 10),candesartancilexetilalone(n = 9)
or in combination with PD123319 (n = 9), PD123319 alone (n = 4), or hydralazine (30mg/kg/day, n = 7). ∗P<0.05 versus control (1-way
ANOVA).
study, it appears that the inability of candesartan cilexetil to
reduce interstitial ﬁbrosis in both adult and senescent SHRs,
results from modiﬁcations of the ECM speciﬁcally related
to hypertension, rather than particularly high pretreatment
basal levels of ﬁbrosis. Indeed, collagen cross-linking has
been shown to be augmented by hypertension [41, 42],
and increased cross-linking is associated with diminished
susceptibility of the ECM to proteolytic degradation [43].
Alteration in ECM degradation due to increased glycation
cross-linking has been associated with decreased activity
of proteolytic enzymes such as matrix metalloproteinase
1 and 2 (MMP-1 and MMP-2) [44], and ﬁndings of
decreasedactivityofMMP-1andMMP-2by40–45%inaged,
hypertensiverats[45]furthersupportthenotionofimpaired
collagen degradative mechanisms in senescent hypertensive
hearts.
On the other hand, the antiﬁbrotic action of AT2R
stimulation on perivascular ﬁbrosis in senescent rats, as
demonstrated in the current investigation, is in accordance
with other chronic in vivo studies, which have also shown
increased cardiac ﬁbrosis during AT2Rb l o c k a d e[ 15, 19,
26]. Similarly, investigators who have used either targeted
deletion [8, 40, 46]o rc a r d i a co v e r e x p r e s s i o n[ 10]o fA T 2R
in mice have also deduced an antiﬁbrotic role of the AT2R.
Importantly, cardiac ﬁbrosis induced by circulating humoral
factors such as Ang II, typically initiates around blood vessels
and then progresses to inﬁltrate interstitial areas, resulting
in a temporal divergence in onset (and thus conceivably also
of regression) of the two types of ﬁbrosis related to location
[47].Inthiscontext,itispossiblethatinterstitialﬁbrosismay
have been reduced by a longer duration treatment with an
AT1R antagonist, as has been reported by other investigators
following AT1Rb l o c k a d ef o r1 2w e e k s[ 15].
In the current study, media-to-lumen ratio of both
aortae and coronary vessels was decreased by candesartan
cilexetil treatment and also by hydralazine in aged SHRs.International Journal of Hypertension 9
This vascular antihypertrophic eﬀect is consistent with
previous reports that increased medial thickness due to
hypertrophy/hyperplasia of smooth muscle cells is closely
related to pressure [48, 49]. However, the other major modi-
ﬁcation of vascularstructurethat occurs in hypertension and
senescence is an increase in vascular collagen content, the
levels of which have been shown to be poorly associated with
MAP, but sensitive to AT1R inhibition [48]. As the vascular
antihypertrophic eﬀect of candesartan cilexetil was reversed,
but MAP was unchanged by PD123319, it is reasonable
to suggest that the eﬀect of AT2R inhibition on vascular
remodellingwaspressure-independentandthusmaybeviaa
reductioninvascularcollagen.Furthermore,suchapressure-
independent inﬂuence of AT2R on collagen accumulation in
aged SHRs is consistent with eﬀects on perivascular ﬁbrosis
in this study, which were decreased by AT1Rb l o c k a d eb u t
unaﬀected by hydralazine, despite both treatments resulting
in similar reductions in MAP.
A limitation of this study was that we did not conﬁrm
that the reversal of ARB-mediated antiﬁbrotic eﬀects by
PD123319 is solely via AT2R mechanisms. Indeed, we [50]
and others have shown that in certain situations, PD123319
may inhibit the eﬀects of Ang 1–7, which is considered the
endogenous ligand for the Mas receptor (MasR). However,
wehavealsorecentlyreportedthatAng1–7showssigniﬁcant
AT2R binding [51], which is consistent with PD123319-
mediated reversal of Ang 1–7 eﬀects being due to inhibition
ofAT2RratherthananonselectiveactionatMasR.Neverthe-
less,deﬁnitiveelucidationofthisissueregardingselectivityof
PD123319 requires future determination of MasR binding.
The present study demonstrates an important role for
AT2R in cardiovascular remodelling in senescent SHRs, as
evidenced by the fact that AT2R inhibition with PD123319
reversed ARB-mediated regression of perivascular ﬁbrosis in
aged SHRs only. Furthermore, we have shown an inhibitory
inﬂuence of AT2R in vascular remodelling, which was appar-
ent in both adult and senescent SHRs, and occurred despite a
lack of AT2R-mediated eﬀects on blood pressure. Given that
our population is aging and that AT1R antagonists are com-
monlyusedantihypertensivesinthisdemographic,thisstudy
provides information regarding the functional relevance of
AT2R in the physiologically relevant setting of hypertension
and senescence, which may have important implications for
optimising cardiovascular therapeutics in the elderly.
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